These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

671 related articles for article (PubMed ID: 34460997)

  • 1. Maternally inherited diabetes and deafness coexists with lipoprotein lipase gene mutation-associated severe hyperlipidemia that was resistant to fenofibrate and atorvastatin, but sensitive to bezafibrate: A case report.
    Zhang X; Chen Y; Tong N; Shao Q; Zhou Y; Mu T; Yang X; Zhang Y
    J Diabetes Investig; 2022 Feb; 13(2):397-401. PubMed ID: 34460997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
    Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.
    Athyros VG; Papageorgiou AA; Athyrou VV; Demitriadis DS; Kontopoulos AG
    Diabetes Care; 2002 Jul; 25(7):1198-202. PubMed ID: 12087019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response.
    Cenarro A; Artieda M; Gonzalvo C; Meriño-Ibarra E; Arístegui R; Gañán A; Díaz C; Sol JM; Pocoví M; Civeira F;
    Am Heart J; 2005 Dec; 150(6):1154-62. PubMed ID: 16338252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate.
    Leiss O; Meyer-Krahmer K; von Bergmann K
    J Lipid Res; 1986 Jul; 27(7):713-23. PubMed ID: 3760707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein Lipase Deficiency Arising in Type V Dyslipidemia.
    Tanaka S; Ueno T; Tsunemi A; Nakamura Y; Kobayashi H; Hatanaka Y; Haketa A; Fukuda N; Soma M; Abe M
    Intern Med; 2019 Jan; 58(2):251-257. PubMed ID: 30210108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.
    Lemieux I; Salomon H; Després JP
    Ann Med; 2003; 35(6):442-8. PubMed ID: 14572169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neonatal hyperlipidemia with pancreatitis: Novel gene mutation of lipoprotein lipase.
    Shah MH; Roshan R; Desai R; Kadam SS
    J Postgrad Med; 2018; 64(4):247-249. PubMed ID: 30147083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
    Arca M; Montali A; Pigna G; Antonini R; Antonini TM; Luigi P; Fraioli A; Mastrantoni M; Maddaloni M; Letizia C
    Metabolism; 2007 Nov; 56(11):1534-41. PubMed ID: 17950105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.
    Brisson D; Ledoux K; Bossé Y; St-Pierre J; Julien P; Perron P; Hudson TJ; Vohl MC; Gaudet D
    Pharmacogenetics; 2002 Jun; 12(4):313-20. PubMed ID: 12042669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extreme diabetic lipaemia associated with a novel lipoprotein lipase gene mutation.
    McLean AG; Petersons CJ; Hooper AJ; Burnett JR; Burt MG; Doogue MP
    Clin Chim Acta; 2009 Aug; 406(1-2):167-9. PubMed ID: 19447100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia.
    Kiortisis DN; Millionis H; Bairaktari E; Elisaf MS
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):631-5. PubMed ID: 11214768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel mutation MT-COIII m.9267G>C and MT-COI m.5913G>A mutation in mitochondrial genes in a Tunisian family with maternally inherited diabetes and deafness (MIDD) associated with severe nephropathy.
    Tabebi M; Mkaouar-Rebai E; Mnif M; Kallabi F; Ben Mahmoud A; Ben Saad W; Charfi N; Keskes-Ammar L; Kamoun H; Abid M; Fakhfakh F
    Biochem Biophys Res Commun; 2015 Apr; 459(3):353-60. PubMed ID: 25701779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment.
    García-Otín AL; Civeira F; Aristegui R; Díaz C; Recalde D; Sol JM; Masramon X; Hernández G; Pocoví M;
    Eur J Clin Invest; 2002 Jun; 32(6):421-8. PubMed ID: 12059987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia.
    Bairaktari ET; Tzallas CS; Tsimihodimos VK; Liberopoulos EN; Miltiadous GA; Elisaf MS
    J Cardiovasc Risk; 1999 Apr; 6(2):113-6. PubMed ID: 10353071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Mutations and Clinical Variability in Maternally Inherited Diabetes and Deafness: An Analysis of 161 Patients.
    Yang M; Xu L; Xu C; Cui Y; Jiang S; Dong J; Liao L
    Front Endocrinol (Lausanne); 2021; 12():728043. PubMed ID: 34899594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands.
    Niho N; Takahashi M; Kitamura T; Shoji Y; Itoh M; Noda T; Sugimura T; Wakabayashi K
    Cancer Res; 2003 Sep; 63(18):6090-5. PubMed ID: 14522940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel unstable mutation in mitochondrial DNA responsible for maternally inherited diabetes and deafness.
    Bannwarth S; Abbassi M; Valéro R; Fragaki K; Dubois N; Vialettes B; Paquis-Flucklinger V
    Diabetes Care; 2011 Dec; 34(12):2591-3. PubMed ID: 21994425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.